BioSpace News Archive

Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter ended June 30, 2022.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) is now commercially available in Canada for people living with amyotrophic lateral sclerosis (ALS).

Salarius Pharmaceuticals, Inc. today announced that the Company will report its second quarter 2022 financial results after the close of the market on Friday, August 5, 2022 and host a conference call and live audio webcast the following Monday, August 8, 2022, at 11:00 a.m. ET, to discuss its financial results.

A jury for the U.S. District Court of Delaware delivered two unanimous verdicts this week in favor of Magnolia Medical Technologies, Inc. (“Magnolia Medical”) in a lawsuit against Kurin, Inc., (“Kurin”) regarding the unlawful use of its innovative Initial Specimen Diversion Device® (ISDD®) technology.

Forecast to 2030,’ thoroughly examines the Warts Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Type 1 Diabetes industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Porphyria industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Osteoarthritis Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Metastatic Prostate Cancer industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Intermittent Claudication industry to provide essential data & information for the targeted readers.